Impact of Bone Microenvironment on PLK Inhibitor Activity in Multiple Myeloma
Author Information
Author(s): Douglas W. McMillin, Jake Delmore, Joseph Negri, Melissa Ooi, Steffen Klippel, Chandrasekhar V. Miduturu, Nathanael S. Gray, Paul G. Richardson, Kenneth C. Anderson, Andrew L. Kung, Constantine S. Mitsiades
Primary Institution: Dana-Farber Cancer Institute
Hypothesis
How does the bone microenvironment influence the effectiveness of Polo-like kinase inhibitors in treating multiple myeloma?
Conclusion
The presence of the bone microenvironment significantly reduces the effectiveness of the PLK inhibitor BI 2536 against multiple myeloma cells.
Supporting Evidence
- BI 2536 showed potent in vitro activity against multiple myeloma cells with IC50 values <40 nM.
- The presence of bone marrow stromal cells decreased the anti-MM activity of BI 2536.
- Clinical trials of BI 2536 have shown limited responses despite high in vitro activity.
- Preclinical models that do not account for the tumor microenvironment may overestimate drug efficacy.
- PLK1 expression was higher in plasma cell leukemia patients compared to those with MGUS.
Takeaway
This study found that a cancer drug works less well when the cancer cells are in their natural environment, which is important for understanding how to treat multiple myeloma.
Methodology
The study used in vitro and in vivo models to assess the activity of the PLK inhibitor BI 2536 in the presence and absence of bone microenvironment components.
Potential Biases
Potential bias in the interpretation of results due to reliance on specific preclinical models.
Limitations
The study primarily focused on preclinical models, which may not fully replicate human responses.
Participant Demographics
The study analyzed gene expression data from 320 myeloma patients.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website